Clinical trial Recruiting at 1 site Observational Ages 12 and up

Using genetics and smartphone data to predict and prevent repeat suicide attempts

Official title: Prevention of Suicidal Behavior Through Therapeutic Interventions Guided by Digital Phenotype and Pharmacogenetics: The SMARTomicS Study Protocol

Run by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · NCT07422090 · Data updated 2026-11-12

This project will try to combine genetic tests and people’s digital behavior to predict which individuals with a past suicide attempt may be at higher risk of trying again.

Quick facts

Study typeObservational
Ages12 Years and up
SexAll
Enrollment5000 (estimated)
SponsorInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Academic / other
Locations1 site (Madrid, Madrid)
StatusRecruiting
StartedApril 1, 2025
Main results expectedDecember 31, 2027
Study endsJanuary 2028
Registry record updatedFebruary 19, 2026
Trial IDNCT07422090 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

People aged 12 and older with at least one prior suicide attempt who can provide a genetic sample and give informed consent (parental consent required for ages 12–17) are the ideal candidates.

Probably not a fit

Those who cannot provide a blood/genetic sample or who do not consent to digital data extraction are unlikely to benefit from participation or from the predictive results.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, multi-site observational cohort that will merge genomic and metabolic profiling with digital phenotyping and clinical records in people with a lifetime history of suicide attempt. Participants (age 12 and up, with parental consent for minors) will be recruited from outpatient mental health clinics, emergency departments, and short-stay hospital units and will provide genetic samples plus consent for extraction of digital data such as Google Takeout. Investigators will link omics, prescription changes, electronic health record data, and standardized suicide-rating scales (e.g., C-SSRS) to develop predictive algorithms for suicidal behavior. Data quality checks and representativeness will be performed using hospital records and national statistics.

Why it matters

Potential benefit: If successful, this approach could help clinicians identify people at higher risk of repeat suicidal behavior earlier and tailor treatments using genetic and digital signal information.

How similar studies have gone: Prior work has found some promising genetic and digital signals related to suicide risk, but fully integrated predictive models combining omics and detailed digital phenotypes remain largely experimental.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. At least one suicide attempt in their lifetime.
2. The attempt must have occurred when the participant was older than 12 years old.
3. Participants must be at least 18 years old or have parental consent if aged 12-17.

Exclusion Criteria:

* medical contraindication prevents blood sample collection
* unable to provide informed consent to participate in the study

Where it's running

  • Instituto Fundación Jiménez Díaz
    Madrid, Madrid, Spain
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.